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Review Article
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Abstract: Biliary tract cancers (BTC) is a group of malignancies that arise from the epithelial cells of the
biliary tree. These cancers are typically classified by anatomic site of origin: intrahepatic cholangiocarcinoma
(IHCC) and extrahepatic cholangiocarcinoma (EHCC), and gallbladder cancer (GBC). To date, complete
surgical resection remains the mainstay of treatment especially for earlier stage disease. Unfortunately, most
patients present with advanced or metastatic disease, when systemic chemotherapy is the only treatment
option. Due to the paucity of effective treatments, BTCs have a dismal prognosis. There is a tremendous
need to better understand the disease biology, discover new therapies, and improve clinical outcomes for this
challenging disease. Next-generation sequencing has produced a more accurate and detailed picture of the
molecular signatures in BTCs. The three BTC histologic subtypes are, in fact, quite molecularly distinct.
IHCC commonly contain FGFR2 fusions and IDH 1 and 2 mutations, whereas EHCC and GBC tend to
carry mutations in EGFR, HER2, and MAPK pathway. In light of this emerging knowledge, clinical trials
have become more biomarker-driven, which allows capturing of subsets of patients that are most likely to
respond to certain therapies. Many new and promising targeted therapeutics are currently in the pipeline.
Here we review the genetic landscape of BTCs while focusing on new molecular targets and targeted
therapeutics currently being investigated in biomarker-driven clinical trials.
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Introduction
Biliary tract cancers (BTC) is a group of rare and
aggressive malignancies arising from the epithelium of
the biliary duct system. They are classified based on
their anatomical site in the biliary tree [intrahepatic
cholangiocarcinoma (IHCC) or extrahepatic
cholangiocarcinoma (EHCC)] or gallbladder cancer (GBC)
(Figure 1). IHCC is the most common BTC and the
second most common hepatic malignancy, accounting for
10–20% of all primary hepatic malignancies (1,2). Owing
to the insidious nature of this group of cancers, they are
usually diagnosed at an advanced stage and carry a dismal
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prognosis. Surgery is potentially curative in early stage
disease. In cases of advanced and metastatic disease, the
current standard of care is systemic chemotherapy with
gemcitabine and cisplatin. Clinical response rates to these
cytotoxic chemotherapies are low, with a 5-year survival of
less than 10% for all three BTC subtypes. In recent years,
we have made strides in our understanding of the disease
biology, as well as advancements in diagnostic techniques
and novel therapeutic strategies. Notably, the genomic
revolution has ushered in an era of high-throughput and
deep molecular profiling, which has provided invaluable
insight into actionable molecular alterations, as well as
their prognostic significance. We have also developed
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Figure 1 Distinct molecular signatures of BTCs. Shown is
a schematic of the biliary tract and gallbladder, along with
common genetic aberrations seen in intrahepatic and extrahepatic
cholangiocarcinoma, and GBC. Red font indicates targetable genes.

a greater appreciation for the molecular heterogeneity
across the BTC subtypes, realizing that these anatomically
classified subgroups exhibit distinct molecular
architectures. Considering this emerging knowledge,
clinical trial design has steered away from the “onesize-fits-all” mentality and has become more biomarkerdriven. Currently there are several ongoing clinical studies
investigating the efficacy of targeted therapies aimed at
populations that underwent biomarker selection. In this
review, we will highlight actionable molecular targets and
their novel targeted therapeutics in current clinical trials.
Epidemiology
The incidence of BTC varies by geography and
demographics, likely due to distinct environmental risk
factors and genetic predisposition. Though BTCs are
traditionally more common in Asian countries, their
incidence has been rising in Western countries in recent
decades (3). Though it is a rare disease, the global incidence
is rising. Chronic inflammation and bile stasis in the biliary
tract are thought to be major risk factors underlying the
pathogenesis of these cancers. Specific risk factors include
primary sclerosing cholangitis, liver fluke (Clonorchis,
Opisthorchis) infection, hepatitis B and C infections,
cholelithiasis or choledocholithiasis, cirrhosis, alcohol,
smoking, and fatty liver disease (3,4).

© Journal of Gastrointestinal Oncology. All rights reserved.

Overall, the 5-year survival rate of BTCs is extremely low
(10% for CCAs and less than 5% for GBC) (5,6). Surgery
is the only potentially curative modality but most patients
are asymptomatic until late in the disease course and
present with locally advanced or metastatic disease. Thus,
only 10–15% of BTCs are amenable to surgery at initial
presentation (7). Even though improved surgical techniques
and better patient selection based on more advanced
radiologic techniques have resulted in better tumor
resection rates, the recurrence rates of these aggressive
cancers remain high at 50–60% (7,8). The role of adjuvant
therapy is poorly-defined and standard regimen is unclear
due to the relative rarity of this disease which hinders large
scale prospective studies (9,10). Therefore, the benefit of
adjuvant treatment is commonly appraised from metaanalyses of multiple small retrospective studies that usually
include more than one, if not all, subtypes of BTC. To
more clearly determine the role of adjuvant treatment, two
phase III randomized controlled trials are currently ongoing
in the Europe to determine the role of adjuvant gemcitabine
plus cisplatin (ACTICCA-1 trial, NCT02170090) or
oxaliplatin (NCT01313377) versus observation for patients
with resected BTC. Before results from these trials are
available, current NCCN guidelines recommend adjuvant
fluoropyrimidine or gemcitabine-based chemotherapy with
consideration of radiation for patients with node-positive
disease or R1/R2 resections.
For patients presenting with unresectable BTCs (locally
advanced, recurrent, or metastatic), the current standard
first-line therapy is a combination of gemcitabine and
cisplatin. This regimen was established by the ABC-02
trial, the largest randomized phase III study to date, which
showed a survival benefit of the combination as opposed
to gemcitabine alone (11.7 vs. 9 months) (11). Other
chemotherapy combinations (e.g., oxaliplatin, 5-FU,
capecitabine, irinotecan) have demonstrated only marginal
improvements in survival (12). Targeted therapies such as
anti-EGFR or anti-VEGF antibodies have so far struggled
to succeed in phase I or II clinical trials. Performing
randomized control trials (RCT) for advanced BTCs has
proven challenging due to the rarity of these malignancies,
lack of effective agents, potential high heterogeneity
within this diagnostic entity, and possibly fundamental
differences among the three BTC subtypes (IHCC, EHCC,
and GBC). In fact, next generation sequencing (NGS)
and transcriptomic analyses have revealed that these BTC
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Table 1 Prevalence of key genetic alterations in biliary tract cancers
Variables

IHCC (%)

EHCC (%)

GBC (%)

References

EGFR

4

3

4–18

(16,17)

HER2

1.5–3

11–18

10–16

(16,18-20)

KRAS

17–30

12–40

0–13

(16,17,19-21)

BRAF

4–7

3

1–6

(16,19,22,23)

PIK3CA

5–6

7–9

8–14

(19,21,24,25)

FGFR2 fusions

6–50

0–5

0–3

(17,19,26-29)

IDH pathway

10–28

0–7

0

(19,21,27,30-32)

ARID1A

17

12

13

(19,27)

BAP1

11

8

0

(17,27)

PBRM1

8

5

7

(17,27)

Tyrosine kinase signaling

Chromatin-remodeling genes

subtypes are molecularly distinct from one another, and
therefore may respond differently to the same treatment
strategy and should not be approached as a single entity for
clinical trial design (13,14). To improve patient outcome,
future clinical trial design must better stratify patients based
on considerations of histologic and molecular subtypes, and
allocate patients to the appropriate targeted agents driven
by biomarkers that could predict treatment response.
Genetic landscape
Before the advent of NGS, our knowledge of genetic
aberrations in BTCs was limited because older
methodologies restricted mutational profiling to a few select
oncogenes or hotspots (15). That technology previously
allowed us to identify key signaling pathways altered in
BTCs, such as the EGFR and vascular endothelial growth
factor receptor (VEGFR) pathways. Thus, many of the
first generation BTC trials targeted EGFR and VEGFR,
but these targeted agents ultimately proved ineffective at
improving clinical outcome (12). NGS, which allows for
characterization of an entire genetic landscape through
gene panels, whole exome, or transcriptome sequencing,
has led to the discovery of many novel actionable mutations
in BTCs (15). Thus, pre-clinical and clinical studies have
expanded from targeting well-established pathways like
EGFR and VEGFR to promising, novel alterations.
Recent studies employing NGS have shed light on
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distinctive molecular spectra across the BTC subtypes
(13,14). FGFR2 gene fusions and mutations in IDH1/2
are predominantly observed in IHCC. KRAS and HER2
mutations are preferentially found in EHCC. Lastly, GBCs
are enriched for mutations in EGFR, HER2, and PIK3CA.
Figure 1 and Table 1 highlight these key genomic alterations
along the biliary tract and gallbladder. Next, we will discuss
key actionable aberrations in BTCs and the novel agents
that target them in biomarker-driven clinical trials.
Tyrosine kinase signaling
EGFR
The EGFR family comprises four tyrosine kinase receptors
(ERBB1–4) that regulate cell proliferation, survival,
angiogenesis, and invasion through ligand binding and
subsequent activation of signal transduction cascades
involving the MAPK pathway (Ras-Raf-MEK-ERK)
and the PI3K/AKT pathway (33) (Figure 2). Aberrant
activation of the EGFR pathway is a common oncogenic
event in BTCs and is associated with tumor recurrence
and worsened outcome (16,18,26,34). Of the EGFR family
members, EGFR (ERBB1) and HER2 (ERBB2) are most
commonly altered in BTCs. Overexpression of EGFR
occurs in 11–27% of IHCC, 5–19% of EHCC (26), and
12% in GBCs (35), whereas activating EGFR mutations are
preferentially seen in GBC (4–18%), but rarely in CCAs
(Table 1) (16,17).
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Figure 2 Key signaling pathways and current targeted therapies. Molecular targeted therapies including drugs currently assessed in phase II/
III trials are highlighted.

Given that EGFR activation regulates several cellular
functions important for carcinogenesis and is one of the
most altered pathways in BTCs, there was strong rationale
to evaluate it as a therapeutic target. However, extensive
clinical testing with EGFR inhibitors has failed to show a
survival benefit in advanced BTCs. Although earlier single
arm phase II trials suggested possible benefits of EGFR
antagonists cetuximab and panitumumab either as single
agents or in combination with chemotherapy (36-39),
larger RCTs of erlotinib, cetuximab or panitumumab in
combination with gemcitabine plus oxaliplatin failed to show
a progression-free survival (PFS) or overall survival (OS)
benefit over chemotherapy alone in advanced BTCs (40,41).
Of note, almost all of these trials have been performed
without stratifying patients by molecular signatures that
could predict response to anti-EGFR agents. In fact,
none has used EGFR genomic alterations as a biomarker.
Additionally, lessons from the colorectal cancer world
have informed us that KRAS mutations negate response
to anti-EGFR therapy (42-44). However, only a few of
the BTC trials have used KRAS status to stratify patients.
A recent phase II trial stratified BTC patients based on
KRAS status, but failed to demonstrate that KRAS status
predicted the population most likely to benefit from antiEGFR therapy (45). Furthermore, two biomarker-driven
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trials that was restricted to KRAS wild-type patients failed
to show a clinically significant improvement in PFS or OS
using panitumumab combined with chemotherapy (46,47).
These studies call into question the utility of KRAS status as
a clinically relevant biomarker predictive of EGFR therapy
response in BTC, as opposed to colon cancer. The relative
importance of mutations in other EGFR pathway genes,
such as BRAF, are being investigated as mechanisms of
resistance to anti-EGFR agents (47,48).
HER2
HER2 overexpression and amplification are predominantly
seen in EHCC and GBCs (10–18% for both) and rarely in
IHCC (Table 1) (16,19,20,26,34,35). Like EGFR-directed
agents, similarly disappointing results came out of trials
with HER2 antagonists (including trastuzumab, lapatinib,
afatinib) combined with chemotherapy in advanced
BTC (49-51). Currently, there is an ongoing phase II trial
with trastuzumab aimed at a selected group of HER2positive BTC patients (Table 2).
VEGF
VEGF is the ligand that binds VEGFR, which initiates
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Table 2 Biomarker-driven clinical trials of biliary tract cancers
Drug(s)

Target

Biomarker selection

Phase

NCT number

Trastuzumab

HER2

HER2

II

NCT02999672

Dabrafenib + trametinib

BRAF, MEK

BRAF V600E

II

NCT02034110

BGJ398

FGFR2

FGFR alterations

II

NCT02150967

BGJ398

FGFR2

FGFR alterations

II

NCT02160041

Ponatinib

FGFR2

FGFR2 fusion

II

NCT02265341

Ponatinib

FGFR2

FGFR alteration

II

NCT02272998

INCB054828

FGFR2

FGFR2 translocation

II

NCT02924376

Erdafitinib

FGFR2

FGFR alteration

II

NCT02699606

ARQ087

FGFR2

FGFR alteration

I/II

NCT01752920

INCB054828

FGFR2

FGFR alteration

I

NCT02393248

AG-120

IDH1

IDH1 mutation

III

NCT02989857

AG-221

IDH2

IDH2 mutation

I/II

NCT02273739

Dasatinib

Multiple kinases

IDH1/2 mutation

II

NCT02428855

AG-120

IDH1

IDH1 mutation

I

NCT02073994

signals to promote cancer growth and metastasis through
stimulating angiogenesis. VEGF is overexpressed in
BTCs and associated with enhanced metastasis, increased
tumor recurrence, and worsened prognosis (34). Studies
with antagonists of the VEGF pathway, including
bevacizumab, cediranib, sorafenib have not yielded
encouraging results (52-56).
MAPK pathway
Aberrations in cell-surface receptors and their ligands
(e.g., EGFR, VEGF) can lead to constitutive activation of
downstream cascades, including the MAPK arm (RAS-RAFMEK-ERK, Figure 2). KRAS is a member of the RAS family
and gain of function mutations in KRAS are one of the most
common events in BTCs, with highest rates seen in EHCC,
followed by IHCC, and lowest in GBC (16,17,19,20,57).
KRAS is associated with lower median survival and
perineural invasion (58). Its frequency also increases with
disease stage (22). BRAF belongs to the RAF family of
kinases that lie directly downstream of RAS (Figure 2).
BRAF mutations are less frequent in BTCs (less than 10%
across all subtypes) and are considered mutually exclusive
with KRAS mutations (16,19,22,59). The most common
BRAF mutation is V600E, but the mutational frequency
is highly varied in BTCs ranging from 0–33% (60).
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The clinical significance of BRAF mutations is less wellestablished, with one study demonstrated an association
with advanced tumor stage, higher likelihood of lymph
node involvement, and worsened survival (22).
Targeting the MAPK pathway has remained a challenge.
Recently, the phase I ABC-04 study of selumetinib, a MEK
inhibitor, in combination with gemcitabine and cisplatin
failed to show clinical benefit in in advanced or metastatic
BTC (61). Even attempts to block multiple components
of the MAPK pathway using multikinase inhibitors
like sorafenib have not proved fruitful (62-65). These
disappointing results are in stark contrast to melanomas,
which frequently harbor the BRAF V600 mutations, where
use of the BRAF inhibitors vemurafenib or dabrafenib has
achieved a striking survival benefit (66-68). Recently, dual
inhibition of BRAF with vemurafenib or dabrafenib and
MEK with trametinib in BRAF V600-mutated melanoma
patients has led to further survival improvements (69-71).
Currently, there is an ongoing phase II trial with dabrafenib
combined with trametinib for BRAF V600-mutated rare
cancers including BTCs (Table 2).
Multiple signaling pathways seem to be involved in the
pathogenesis of BTCs, rendering the decision of which
pathways to target challenging. Moreover, no oncogene
addiction pathway has been pinpointed. Targeting single
pathways either as monotherapy or in combination with
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chemotherapy has shown varying degrees of improvements
in response rates, but these have not translated to clinically
significant increases in PFS or OS. Currently, some clinical
trials are using a multi-target approach by using multikinase
inhibitors or a combinatorial approach with multiple agents
aimed at different pathways (12,72). Results from studies
using multikinase inhibitors regorafenib and pazopanib are
anxiously awaited.
Novel targets
Over the recent years, genomic profiling using NGS has
revealed the presence of novel alterations in BTCs such
as recurrent fusion events (FGFR2 and ROS1 fusions),
somatic mutations in metabolic enzymes (IDH1 and 2)
(17-19,21,23,26-31,57,73,74), and chromatin-remodeling
genes (ARID1A, BAP1, PBRM1) (17,19,27).
FGFR2 fusions
FGFR2 is a member of the fibroblast growth factor
family of receptor tyrosine kinases that regulate cell
proliferation, differentiation, apoptosis (75). Alterations in
this pathway through activating mutations, amplifications,
or chromosomal translocation have been implicated in
malignant transformation (76). Chromosomal fusions
occur between exons 1–19 of FGFR2 and various genomic
partners (e.g., AHCYL1, BICC1, PARK2, KCTD1, MGEA5,
TACC3, TXLNA) in BTCs (17,19,26-29). The resulting
fusion protein undergoes ligand-independent dimerization
and subsequent autophosphorylation, which leads to
constitutive activation of downstream signaling pathways,
such as MAPK (76) (Figure 2). The oncogenic potential of
FGFR2 fusions has been demonstrated in vitro (23,28,77,78)
and in vivo (28). Screening for fusions by massive parallel
sequencing or FISH-based assays has revealed a wide range
of IHCC (6–50%) containing FGFR2 fusions, whereas
EHCC and GBC rarely do (Table 1).
In preclinical studies, the presence of FGFR2 fusions
seems to predict high sensitivity to FGFR2 inhibitors
(23,28,73,77,78). This provided the catalyst to target the
FGFR pathway specifically in tumors harboring these
fusions. FGF pathway antagonists include small molecule
tyrosine kinase inhibitors that act at the receptor level
to suppress oncogenic signaling (28). Clinical efficacy of
FGFR2 inhibitors is being investigated in biomarker-driven
clinical trials aimed at patients harboring FGFR2 pathway
alterations (Table 2). The pan-FGFR inhibitor BGJ398 has
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potent activity against FGFR1–3 and is under evaluation in
advanced CCAs with FGFR genetic alterations in two phase
II studies (Table 2). Preliminary results from one of the
studies (NCT02150967) was recently reported. Amongst
the 26 patients with advanced or metastatic CCA harboring
FGFR2 fusions or other alterations, the disease control
rate was 82% (79). The drug was well tolerated except for
hyperphosphatemia.
Ponatinib is an example of a non-selective pan-FGFR
inhibitor that is far along in clinical development. In a
preclinical study, treatment with ponatinib resulted in
biochemical CA 19-9 response with tumor shrinkage in a
patient with the FGFR-MGEA5 fusion (73). Another patient
in the study with FGFR-TACC3I fusion whose disease had
progressed on pazopanib (another non-selective FGFR
inhibitor) was treated with ponatinib therapy, resulting
in stabilization of disease (73). This preliminary evidence
supported assessing the anti-tumor activity of ponatinib
in clinical trials. Ponatinib is being investigated in a phase
II trial of advanced BTCs harboring FGFR2 gene fusions
detected by either NGS or FISH (NCT02265341, Table 2).
Another ongoing phase II trial is assessing the efficacy of
ponatinib in advanced malignancies including CCA with
any FGFR aberrations (mutations, fusions, amplifications)
(NCT02272998, Table 2).
Other ongoing phase II studies include oral panFGFR selective small molecular inhibitors INCB054828,
erdafitinib (JNJ-42756493), ARQ087 (Table 2). Preclinical
and phase I studies have suggested that these compounds
have potent and selective anti-tumor activity against FGFRmutated cancers (80-83). A recently developed monoclonal
antibody against FGFR2 (BAY1179470) showed tumor
suppressive potential in tumors with high FGFR2
expression (84). Phase I testing of this antibody just recently
completed (NCT01881217). Another phase I trial with
oral pan-FGFR inhibitor AZD4547 also just completed
(NCT00979134).
IDH1/2
IDH1 and IDH2 encode metabolic enzymes that participate
in the Krebs cycle. Mutations in IDH1 and IDH2 result in
the accumulation of the oncometabolite 2-hydroxyglutarate,
which affects cell differentiation, survival, as well as DNA
methylation. The epigenetic alterations caused by mutations
in IDH1/2 lead to a blockade of hepatocyte differentiation,
causing an increase in hepatic progenitor cells, which
eventually results in tumorigenesis (85). IDH mutations
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have been seen in solid tumors, including gliomas, and
recently identified in BTCs. They occur primarily in IHCC
(10–28%) and rarely in EHCC and GBCs (19,21,27,30,31)
(Table 1). The most common IDH1 and IDH2 mutations
cluster at the hotspot codons 132 and 172, respectively (86).
The prognostic significance of these mutations remains to
be fully elucidated, as there is some conflicting data. Two
studies have correlated IDH mutations with decreased
survival in IHCC compared to wild-type cases (27,31).
Another study failed to demonstrate an association between
IDH mutation status and survival (32). In contrast, a large
cohort of IHCC samples (n=326) showed IDH mutations
were associated with longer time to recurrence (30).
The efficacy of pharmacologically targeting the mutant
IDH enzymes has been demonstrated in other types of
tumors. IDH1 inhibitor AGI-5198 slowed the growth of
IDH-mutant glioma cells (87) and IDH2 inhibitor AGI6780 selectively inhibited the growth of leukemic cells
carrying mutant IDH2/R140Q (30). The role of IDH
inhibitors in IHCC is currently being investigated. AG120, an IDH1 inhibitor, has been shown to transiently
stabilize disease progression in patients with IDH1mutant IHCC. The expansion phase is currently underway
(NCT02073994, Table 2). AG-120 is also being tested in
the ongoing phase III RCT “ClarIDHy” in patients with
advanced or metastatic CCA carrying an IDH1 mutation
(Table 2). A phase I/II trial with AG-221 (IDH2 inhibitor)
has just completed. A recent study showed that a subset of
IHCC tumors with IDH mutations are exquisitely sensitive
to the multikinase inhibitor dasatinib (88). This evidence
paved the way for designing a phase II trial using dasatinib
in IHCC cases harboring mutations in IDH1 or 2 (Table 2).
Other agents that have demonstrated preclinical efficacy
and are now in phase I testing include BAY1436032 (IDH1
inhibitor), IDH305 (IDH1 inhibitor), and AG-881 (IDH1/2
inhibitor) (89).

being tested in CCAs carrying ROS1 gene fusions.
Conclusions
BTCs are highly aggressive tumors that carry a dismal
prognosis. Historically, the BTC subtypes have been
studied as a single entity. Application of NGS technologies
has allowed for enhanced characterization of the distinct
genetic landscapes in the various BTC subtypes. FGF
and IDH pathway alterations are commonly seen in
IHCC, whereas alterations in the EGFR-MAPK-PI3K
pathway occur more frequently in EHCC and GBC. The
molecular heterogeneity across these subtypes likely confers
differential responses to various treatments. Thus, therapy
should be customized based on mutational spectra. To
optimize clinical trial design, targeted therapies should
be matched to specific molecular alterations through
patient biomarker selection. Past investigations into agents
targeting receptor tyrosine kinase and MAPK pathways have
not shown significant benefit over standard chemotherapy
regimen. However, improvements in genetic profiling have
unveiled novel actionable mutations, such as FGFR2 fusion
proteins and mutated IDH1/2. Agents targeted against these
newly discovered aberrations are being actively investigated
in clinical trials and hold the promise of improving clinical
outcomes in this devastating orphan disease.
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ROS1
ROS1 kinase fusions between kinase domain of ROS and
FIG have been found in 8.7% of CCAs (74). The resultant
FIG-ROS1 fusion protein has oncogenic potential in
vitro and in vivo and can be inhibited by pharmacological
targeting (74,90). A phase II trial of crizotinib (ALK/ROS1
inhibitor) in patients with ALK, MET, or ROS1 alterations
is underway (Table 2). LDK378, a ALK/ROS1 inhibitor, is
being investigated in ROS1-overexpressing advanced CCAs
(Table 2). Entrectinib, another ALK/ROS1 inhibitor, is
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